Combination Lenalidomide and Azacitidine:A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia by Craddock, Charles et al.
 
 
University of Birmingham
Combination Lenalidomide and Azacitidine
Craddock, Charles; Slade, Daniel; De Santo, Carmela; Wheat, Rachel; Ferguson, Paul;
Hodgkinson, Andrea; Brock, Kristian; Cavenagh, Jamie; Ingram, Wendy; Dennis, Mike;
Malladi, Ram; Siddique, Shamyla; Mussai, Francis; Yap, Christina
DOI:
10.1200/JCO.18.00889
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Craddock, C, Slade, D, De Santo, C, Wheat, R, Ferguson, P, Hodgkinson, A, Brock, K, Cavenagh, J, Ingram, W,
Dennis, M, Malladi, R, Siddique, S, Mussai, F & Yap, C 2019, 'Combination Lenalidomide and Azacitidine: A
Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid
Leukemia', Journal of Clinical Oncology , vol. 37, no. 7, JCO1800889, pp. 580-588.
https://doi.org/10.1200/JCO.18.00889
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
original
report
Combination Lenalidomide and Azacitidine: A
Novel Salvage Therapy in Patients Who Relapse
After Allogeneic Stem-Cell Transplantation for
Acute Myeloid Leukemia
Charles Craddock, MD1,2; Daniel Slade, MSc2; Carmela De Santo, PhD2; Rachel Wheat, MSc2; Paul Ferguson, MD3;
Andrea Hodgkinson, PhD2; Kristian Brock, MSc2; Jamie Cavenagh, MD4; Wendy Ingram, MD5; Mike Dennis, MD6; Ram Malladi, MD1;
Shamyla Siddique, MPhil2; Francis Mussai, MD2; and Christina Yap, PhD2
abstract
PURPOSE Salvage options for patients who relapse after allogeneic stem-cell transplantation (allo-SCT) for acute
myeloid leukemia (AML) and myelodysplasia (MDS) remain limited, and novel treatment strategies are required.
Both lenalidomide (LEN) and azacitidine (AZA) possess signiﬁcant antitumor activity effect in AML. Admin-
istration of LEN post-transplantation is associated with excessive rates of graft-versus-host disease (GVHD), but
AZA has been shown to ameliorate GVHD in murine transplantation models. We therefore examined the
tolerability and activity of combined LEN/AZA administration in post-transplantation relapse.
PATIENTS AND METHODS Twenty-nine patients who had relapsed after allo-SCT for AML (n = 24) or MDS (n = 5)
were treated with sequential AZA (75 mg/m2 for 7 days) followed by escalating doses of LEN on days 10 to 30.
Dose allocation and maximum tolerated dose (MTD) estimation were guided by a modiﬁed Bayesian continuous
reassessment method (CRM).
RESULTS Sequential AZA and LEN therapy was well tolerated. The MTD of post-transplantation LEN, in
combination with AZA, was determined as 25 mg daily. Three patients developed grade 2 to 4 GVHD. There was
no GVHD-related mortality. Seven of 15 (47%) patients achieved a major clinical response after LEN/AZA
therapy. CD8+ T cells demonstrated impaired interferon-g/tumor necrosis factor–a production at relapse, which
was not reversed during LEN/AZA administration.
CONCLUSION We conclude LEN can be administered safely post-allograft in conjunction with AZA, and this com-
bination demonstrates clinical activity in relapsed AML/MDS without reversing biologic features of T-cell exhaustion.
The use of a CRM model delivered improved efﬁciency in MTD assessment and provided additional ﬂexibility.
Combined LEN/AZA therapy represents a novel and active salvage therapy in patients who had relapsed post-allograft.
J Clin Oncol 37. © 2019 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
Allogeneic stem-cell transplantation (allo-SCT) plays
an increasingly important role in the management of
acute myeloid leukemia (AML) and myelodysplasia
(MDS) consequent on the advent of reduced-intensity
conditioning regimens and increased availability of
alternative donors.1 However, 30% to 80% of patients
receiving allografts for AML are destined to relapse,
and fewer than 10% survive long term.2 Consequently,
relapse is now the major cause of treatment failure in
patients receiving allografts for AML/MDS.3 Although a
second allograft and donor lymphocyte infusion (DLI)
both have the capacity to deliver durable survival in
patients with recurrent disease, they are only effective in
patients who achieve a morphologic complete re-
mission (CR) after salvage therapy.4,5 Currently, salvage
options are highly unsatisfactory. Intensive chemo-
therapy results in acquisition of a CR in a proportion of
patients who had relapsed post-transplantation, but it is
toxic and often poorly tolerated.6 As a consequence,
most patients who relapse after an allograft are palliated,
and the development of effective salvage regimens
represents a major unmet need.
Recently, both the DNA methyltransferase inhibitor
azacitidine (AZA) and the immunomodulatory drug
lenalidomide (LEN) have been shown to possess sig-
niﬁcant antileukemic activity in newly diagnosed AML
and beneﬁt from a broadly favorable toxicity proﬁle.7,8 In
patients who relapse after allo-SCT, AZA is well toler-
ated, and 15% to 20% of patients achieve a CR after a
median of 108 days from the commencement of AZA
therapy.9 Strategies with the ability to increase the
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activity of AZAmonotherapy are therefore required. Although
low-dose LEN demonstrates antileukemic activity in patients
who relapse after allo-SCT, it is associated with high rates of
severe, often life-threatening, graft-versus-host disease
(GVHD), and its administration is generally viewed to be
contraindicated post-transplantation.10,11 In addition to its
antileukemic activity, AZA accelerates reconstitution of
T-regulatory cells post-transplantation in murine models,
resulting in a reduced risk of severe GVHD.12 These ob-
servations have been replicated in patients allografted for
AML.13-15We therefore hypothesized that coadministration of
AZA may deliver additive antileukemic activity while serving
to ameliorate the risk of severe GVHD associated with LEN
administration post-transplantation.
A major factor limiting the expeditious examination of novel
drug combinations in complex clinical settings, such as
post-transplantation relapse, has been the limitations of
standard early-phase trial designs conventionally used to
establish the maximum tolerated dose (MTD).16,17 Emerging
data have highlighted the superior performance of model-
based designs, such as the continuous reassessment
method (CRM), in correctly identifying the MTD by per-
mitting more efﬁcient patient allocation, thereby enabling a
more rapid progression to later phases of clinical trial
assessment.18,19 We therefore examined the tolerability and
activity of combined LEN/AZA therapy in patients who had
relapsed after allo-SCT for AML using dose transition
pathways (DTP). DTP is a useful design calibration tool
used to provide a tailored CRM design integrating important
clinical judgements in a revised statistical model, ensuring
applicability in practice before implementation, and an
operational tool to guide the process of making dose
escalation/de-escalation decisions.20
PATIENTS AND METHODS
Eligibility
The VIOLA trial (ISCRCTN98163167, EudraCT 2013-
002118-11) was delivered by the Bloodwise Trials Accel-
eration Program as a prospective, open-label, phase I dose-
ﬁnding, multicenter trial designed to determine the MTD of
LEN in combination with AZA in patients who have relapsed
after allo-SCT for AML or MDS. Patients with active acute or
chronic GVHD or a history of grade 3 or 4 GVHD were ex-
cluded. Impaired renal or hepatic function (deﬁned as total
bilirubin greater than or equal to 2.5 times the upper limit of
normal (ULN), aspartate aminotransferase or alanine ami-
notransferase greater than or equal to 3.0 times the ULN,
and estimated glomerular ﬁltration rate less than or equal to
40 mL/min) were exclusion criteria. Patients receiving im-
munosuppressive therapies at the time of relapse and those
who had received antitumor therapies within 28 days before
the start of protocol treatment were also excluded.
Trial Design and Assessment of Safety and Response
Patients were recruited sequentially in planned cohort sizes
of three, with amaximum sample size of 30. AZA (75mg/m2)
was administered by subcutaneous injection on a 5 + 2 + 2
schedule, commencing on day 1 of a 42-day cycle for up
to six cycles. A predetermined dose level of LEN was ad-
ministered from days 10 to 30, followed by a 12-day rest
period according to a modiﬁed one-stage, one-parameter
Bayesian CRM (Table 1). Tolerability and safety were
assessed according to the National Cancer Institute
Common Terminology Criteria for Adverse Events v4.0 for
all patients who commenced treatment. Response to trial
therapy was assessed using modiﬁed Cheson criteria.21
Patients achieving a major clinical response—deﬁned as
a CR, CR with incomplete blood count recovery, or partial
response (PR)—within the ﬁrst six cycles of treatment were
permitted to continue study treatment until loss of re-
sponse. Patients who were nonresponding discontinued
trial therapy. A dose-limiting toxicity (DLT) was deﬁned as
the occurrence of grade 3 or 4 acute GVHD, recurrent
grade 2 acute GVHD, any increase in GVHD grade within
the ﬁrst two cycles of therapy, or grade 2 GVHD persisting
for 42 or more days. New-onset grade 3 or 4 non-
hematologic toxicity or death related to treatment were also
considered to be DLTs and were formally evaluated up to
the end of cycle 1 treatment (day 30).
TABLE 1. Dose Levels and Prior and Posterior Probabilities of DLTs for Each Dose Level With Associated 90% Probability Intervals (based on the
CRM dose-toxicity model)
Combination Dose of LEN
With 75 mg/m2 AZA Prior DLT Rate
No. of Evaluable
Patients
No. of
DLTs
Posterior DLT Rate (90%
probability interval)
Dose 22 (AZA only) 0.03 0* 0* 0.001 (0-0.012)
Dose 21 (2.5 mg LEN) 0.07 0* 0* 0.004 (0-0.035)
Dose 0 (5 mg LEN) 0.12 3 0 0.013 (0.001-0.068)
Dose 1 (10 mg LEN) 0.20 3 0 0.037 (0.005-0.131)
Dose 2 (15 mg LEN) 0.30 2 0 0.085 (0.019-0.218)
Dose 3 (25 mg LEN) 0.40 13 2 0.153 (0.048-0.314)
Dose 4 (35 mg LEN) 0.52 0* 0* 0.263 (0.115-0.437)
Abbreviations: AZA, azacitidine; CRM, continuous reassessment method; DLT, dose-limiting toxicity; LEN, lenalidomide.
*Untested doses.
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CRM Model for Assessment of the MTD
An empirical dose-toxicity model was used to calculate
estimates of the probability of occurrence of DLT for the
investigated doses and recommended dose escalation/
de-escalation on the basis of the investigators’ experience
andpublished data (Table 1).18,22 A normal prior ofmean0 and
variance 0.75 for the slope parameter was assumed. The
prior guess of MTD was dose 1, but given the reports of
severe GVHD occurring with relatively low doses of LEN
post-transplantation, a cautious starting dose for the ﬁrst
cohort of patients was decided at dose 0. On the basis of the
DLT outcomes of the ﬁrst cohort, posterior DLT probabilities
at all dose levels were computed. The recommended dose
level for the second cohort was the dose with updated DLT
rate closest to the target level of 20%, incorporating any
additional restrictions, such as no skipping of doses in
escalation. This continued for the subsequent cohorts until
the maximum sample size was reached or if stopped early.
Given the complexity of the trial population under study, the
proposed CRM design incorporated practical modiﬁcations
to create a tailored model, allowing the trial to stop early if
there are at least 12 patients who recieved a dosage at the
MTD level and there is strong evidence that the lowest dose
is too toxic. Using the DTP tool, the Bayesian stopping-early
criterion was calibrated such that the trial stopped early if
there was a high chance (greater than 72%) that the
posterior probability of DLT at the lowest dose was more
than 10% greater than the target DLT rate of 20%.20 For
CRM modeling, source code obtained from R package
dfcrm was modiﬁed to incorporate practical modiﬁcations
to the design.
Immune Evaluation
The frequency of CD3+ T cells and CD4+FOXP3+
T-regulatory cells was analyzed in all samples by a CyAn
ﬂow Cytometer (Beckman Coulter, High Wycombe,
Buckinghamshire, UK). Expression of CD3, CD4, and
forkhead box 3 (FOXP3) (BioLegend, San Diego, California,
USA) in combination with Programmed cell death protein 1
(PD1), Lymphocyte-activation gene 3 (LAG3), and T-cell
immunoglobulin and mucin-domain containing-3 (BioLegend)
exhaustion markers were investigated on frozen pe-
ripheral blood mononuclear cell samples. To assess the
activation status of these T cells, 0.5 3 106 peripheral-
blood mononuclear cells were treated with 20 ng/mL
phorbol 12-myristate 13-acetate (Sigma, St Louis, Missouri,
USA) and 500 ng/mL ionomycin (Sigma) in vitro for 48
hours. Supernatants were harvested and the cytokine
proﬁle was analyzed by bead-array ﬂow cytometry
(BioLegend).
Patients recruited
 (N = 31)
Patients received treatment
 (n = 29)
5 mg lenalidomide plus
75 mg/m2 azacitidine
(n = 4) 
10 mg lenalidomide plus
75 mg/m2 azacitidine
(n = 5)
15 mg lenalidomide plus
75 mg/m2 azacitidine
(n = 5)
25 mg lenalidomide plus
75 mg/m2 azacitidine
(n = 15)
Enrollment
Allocation
Follow-Up: Cycle 1
Analysis*
Did not start treatment
Died as a result of disease progression   
Inadequate liver function
(n = 2)
(n = 1)
(n = 1)
Died
(n = 1)
Died
Insufficient treatment:
Grade 2 GVHD
Rash  
(n = 1)
(n = 2)
Died
Insufficient treatment:
SAE febrile
neutropenia 
(n = 1)
(n = 1)
Died
Insufficient treatment:
SAE febrile
neutropenia plus
diarrhea 
(n = 1)
(n = 1)
Evaluable (n = 3)
No DLT
Evaluable (n = 3)
No DLT
Evaluable (n = 2†)
No DLT
Evaluable
2 patients had a DLT
Fatigue and rash
Deranged LFTs
(n = 1)
(n = 1)
(n = 13†)
FIG 1. Flow diagram of participants summarizing patient ﬂow from trial entry, detailing evaluability for maximum tolerated dose (MTD) determination. (*) A
patient was considered to be evaluable for MTD determination if they received all seven doses of azacitidine and at least 80% (17 days) of lenalidomide in
cycle 1 of treatment; those who withdrew/died for reasons that were deemed to be non–treatment related in cycle 1 were classed as inevaluable and were
replaced accordingly. (†) One patient was treated incorrectly with the higher dose (25 mg lenalidomide plus 75 mg/m2 azacitidine) for cycle 1 rather than
15mg lenalidomide plus 75mg/m2 azacitidine and so was included in the higher dose level for the analysis. The patient reverted to the correct assigned dose
level for the proceeding cycles. DLT, dose-limiting toxicity; GVHD, graft-versus-host disease; LFT, liver function tests; SAE, serious adverse event.
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Statistical Estimation
The MTD was deﬁned as the dose level with an estimated
DLT rate closest to 20% (target) with its associated DLT rate
and 90% probability interval. The DLT evaluable population
included those patients who had received all 7 days of AZA
and at least 17 of 21 days of LEN in cycle 1. The overall
survival (OS) curves for responders and nonresponders
were generated using Kaplan-Meier plot and compared
using the log-rank test. For immune evaluation analysis,
two-tailed Mann-Whitney U test or Wilcoxon signed-rank
test for unpaired and paired samples, respectively, were
performed. Statistical analyses were conducted using R
version 3.4.2 and GraphPad Prism version 6.0h (GraphPad
Software, La Jolla CA). P values , .05 were considered
statistically signiﬁcant.
RESULTS
Patient Characteristics
Thirty-one patients who had relapsed after an allograft for
AML or MDS were recruited between February 2014 and
December 2016. Twenty-nine patients commenced trial
therapy (AML, n = 24; MDS, n = 5; Fig 1; Table 2) with a
median follow-up of 23 months. The mean percentage
blasts at commencement of treatment was 40%, and the
median time from transplantation to relapse before the trial
was 10 months. Patients received a median of three cycles
of therapy in the study (range, 0 to 11).
MTD Assessment
Twenty-one patients were evaluable for MTD assessment
(Fig 1). Sequential updates of the estimated dose-toxicity
curves were determined using the CRM (from initial prior
curve) after each cohort (Appendix Fig A1, online only), and
the ﬁnal model’s estimated posterior probabilities of DLT for
each dose level and their associated 90% probability in-
tervals were calculated (Table 1). The MTD for LEN when
administered with AZA was determined as 25 mg on the
basis of an estimated posterior probability of DLT of 15.3%
(90% probability interval, 4.8% to 31.4%). Thirteen of 21
(62%) evaluable patients were treated at the MTD. The
maximum likelihood estimate of the DLT rate at the model-
determined MTD and an associated 95% CI (Clopper-
Pearson) is 15.4% (1.9% to 45.5%). Sequential dose
decisions made by the Trial Steering Committee after each
cohort are presented in Appendix Figure A2 (online only).
Assessment of Safety
Twenty treatment-related nonhematologic toxicities oc-
curred in more than 10% of patients at grade 3 or greater at
any time from cycle 1 through all cycles of treatment
(Table 3). Three patients developed acute GVHD during
therapy. One developed grade 2 lower gut GVHD after
receiving four cycles of LEN at a dose of 15 mg. Two
patients receiving 25 mg LEN developed GVHD: one with
grade 2 acute skin GVHD in cycle 1 and one with grade 3
liver GVHD during cycle 6 of therapy. All patients who
developed GVHD responded to steroid therapy, and there
were no GVHD-related deaths. Two DLTs occurred in
patients receiving 25 mg of LEN. One patient developed
fatigue and rash (grade 3); the other experienced deranged
liver function tests (grade 3). Twenty-two patients died: 19
from resistant or progressive disease and three from in-
fectious complications.
Clinical Response and OS
Seven of 15 (47%) patients who received at least three
cycles of treatment achieved a major clinical response to
LEN/AZA salvage (CR, n = 3; CR with incomplete blood
count recovery, n = 3; PR, n = 1). Of the seven responders,
six patients had AML and one MDS. The mean age was
52 years (range, 28 to 68 years). The mean percent blasts
TABLE 2. Baseline Patient Characteristics: Safety Population (n = 29)
Characteristic No. (%)
Disease
AML 24 (83)
MDS 5 (17)
Age (years), mean (range) 54 (18-73)
Cytogenetic risk group
Favorable risk 3 (10)
Intermediate risk 18 (64)
Poor risk 7 (23)
Not known 1 (3)
Conditioning regimen
Reduced intensity 25 (86)
Myeloablative 4 (14)
Donor
HLA-identical sibling 13 (45)
Unrelated donor 16 (55)
Prior acute GVHD
No 22 (76)
Yes 7 (24)
ECOG performance status
0 20 (69)
1 8 (28)
Not known 1 (3)
Blasts at baseline (%)
Mean (range) 40 (7-90)
Not known 8 (28)
Relapse: time from transplantation (months)
Median (range) 10 (1-39)
Not known 1 (3)
Abbreviations: AML, acute myeloid leukemia; ECOG, Eastern
Cooperative Oncology Group; GVHD, graft-versus-host disease; HLA,
human leukocyte antigen; MDS, myelodysplasia.
4 © 2019 by American Society of Clinical Oncology
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at baseline was 18% (range, 7% to 34%). The median time
from transplantation to relapse was 11 months (range, 4 to
31 months). There was no correlation between the ad-
ministered dose of LEN and the response rate (Table 4).
Five patients who achieved a major clinical response
subsequently received DLI (n = 3) or a second allograft (n =
2). Of the three patients who received DLI, two patients are
still alive 15 and 35 months after trial therapy commenced.
One patient is still alive after a second transplantation,
22 months after commencing trial therapy. The median OS
in patients who responded to treatment was 27 months,
compared with 10 months in nonresponders (P = .004;
Appendix Fig A3, online only). In the total cohort of 29
patients receiving at least one dose of LEN/AZA, the re-
sponse rate was 24% (seven of 29), which likely reﬂected
limited exposure to trial therapy, most commonly because
of progressive disease.
Immune Evaluation
Exposure to both AZA and LEN can induce differences in
T-cell activation and function in vitro, and we therefore
sequentially characterized the number and phenotype of
CD3+ T cells in patients before and after trial therapy. A
signiﬁcant reduction in the frequency of T cells was ob-
served before commencement of trial therapy, compared
with healthy controls (P , .001; Fig 2A). T cells from trial
patients at baseline expressed increased LAG3 and PD1,
consistent with an exhaustion phenotype (Figs 2B and 2C).
No CD4+FOXP3+ T cells were identiﬁed. T cells from trial
patients demonstrated a signiﬁcant reduction in release of
T helper 1 cells cytokines interferon-g and tumor necrosis
factor–a after phorbol 12-myristate 13-acetate-ionomycin
stimulation (P, .001) compared with healthy controls (Fig
2D). Release of proinﬂammatory cytokines IL-2, IL-5, and
IL-6 were similarly reduced (Appendix Figs 4A-4C, online
only).
The seven patients who demonstrated a clinical response
(CR or PR) to combined AZA and LEN trial therapy were
additionally evaluated. The CD3+ T-cell frequency in the
peripheral blood did not increase after six cycles of trial
therapy (Fig 2E). No signiﬁcant changes in the frequency of
PD1/LAG3+ T cells (Fig 2F) or cytokine proﬁle (Fig 2G) were
identiﬁed after trial therapy. Taken together, these ﬁndings
indicate that T-cell function is impaired in patients who
relapse post-allograft consistent with an exhaustion phe-
notype, and that LEN/AZA treatment exerts antitumor ac-
tivity independent of this pathway.
DISCUSSION
The demonstration that high doses of LEN, in combination
with AZA, exert signiﬁcant antileukemic activity withmodest
toxicity in patients who relapse after allo-SCT identiﬁes a
potentially important new salvage strategy in patients
who relapse post-transplantation. Intensive chemotherapy
is often ineffective in this setting and associated with
TABLE 4. Best Response to Trial Therapy in 15 Evaluable Patients
Best Response Overall
Combination Dose of LEN with 75 mg/m2 AZA
Dose 0 (5 mg LEN) Dose 1 (10 mg LEN) Dose 2 (15 mg LEN) Dose 3 (25 mg LEN)
CR 3 (20) 1 (33.3) 0 (0) 0 (0) 2 (25)
CRi 3 (20) 0 (0) 1 (50) 2 (100) 0 (0)
PR 1 (6.7) 0 (0) 0 (0) 0 (0) 1 (12.5)
Resistant disease 7 (46.7) 1 (33.3) 1 (50) 0 (0) 5 (62.5)
Not evaluable 1 (6.7) 1 (33.3) 0 (0) 0 (0) 0 (0)
NOTE. Data presented as No. (%).
Abbreviations: AZA, azacitidine; CR, complete remission; CRi, complete remission with incomplete blood count recovery; LEN, lenalidomide; PR, partial
response.
TABLE 3. Grade 3 or Greater Treatment-Related Nonhematologic Adverse Events Observed in 10% or More of the Trial Population
Event Grade Overall
Combination Dose of LEN With 75 mg/m2 AZA
Dose 0 (5 mg LEN) Dose 1 (10 mg LEN) Dose 2 (15 mg LEN) Dose 3 (25 mg LEN)
Febrile neutropenia 3 9 (6) 1 (1) 1 (1) 0 (0) 7 (4)
4 1 (1) 0 (0) 0 (0) 1 (1) 0 (0)
Infections and infestations 3 4 (3) 0 (0) 0 (0) 1 (1) 3 (2)
Sepsis 3 2 (2) 0 (0) 0 (0) 0 (0) 2 (2)
4 4 (3) 0 (0) 0 (0) 0 (0) 4 (3)
NOTE. Data presented as events (patients) unless otherwise noted.
Abbreviations: AZA, azacitidine; LEN, lenalidomide.
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FIG 2. Cell numbers and cytokine expression in healthy controls and trial patients. (A) The frequency of CD3+ T cells in peripheral-blood
mononuclear cells (PBMCs) from healthy donors and trial patients. (B) Expression of T-cell surface marker Lymphocyte-activation gene 3
(LAG3) in healthy donors and trial patients. (C) Expression of T-cell surfacemarker Programmed cell death protein 1 (PD1) in healthy donors
and trial patients. (D) Expression of T helper 1 cells (Th1) cytokines interferon (IFN)-g and tumor necrosis factor (TNF)-a after phorbol 12-
myristate 13-acetate ionomycin stimulation in healthy donors and trial patients. (E) Frequency of CD3+ T cells before and after com-
mencement of trial therapy in patients demonstrating a clinical response to trial therapy. (F) Functional status of T cells in patients who
demonstrated a clinical response to trial therapy as determined by LAG3 and PD1 expression. (G) Expression of Th1 cytokines IFN-g and
TNF-a after phorbol 12-myristate 13-acetate ionomycin stimulation in patients achieving a clinical response to trial therapy.
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substantial toxicity. Although the targeted therapies sor-
afenib and AG221 demonstrate signiﬁcant clinical activity
in patients with relapsed disease post-allograft their use is
restricted to speciﬁc biologic subtypes of AML.23,24 Our
data, for the ﬁrst time to our knowledge, demonstrate that
LEN can be safely administered post-allograft in combi-
nation with AZA, and seems to be associated with a higher
CR/PR rate than AZA monotherapy.9 The observed clinical
activity may be consequent on the additive antileukemic
activity of LEN and AZA or alternatively represent phar-
macologic manipulation of the graft-versus-leukemia effect.
AZA has previously been shown to up-regulate tumor an-
tigen expression on AML blasts and can also induce a CD8+
T-cell response post-allograft, whereas LEN has direct
T-cell activation properties.13
A striking observation in this study was the tolerability of
LEN after allo-SCT. Previous studies using LEN as main-
tenance or pre-emptive therapy in the ﬁrst 3 months post-
transplantation reported excessive rates of severe GVHD
after LEN administration, even at modest doses of 5 to
10 mg. In contrast, in this study patients tolerated doses of
up to 25 mg LEN, in conjunction with AZA, with acceptable
rates of GVHD. Why then might this study have yielded
results different from previous reports? It may be relevant
that the majority of patients treated with LEN maintenance
in previous studies were recipients of T-replete allografts,
whereas patients in this series received either alemtuzu-
mab or anti-thymocyte globulin as GVHD prophylaxis. Al-
ternatively, the coadministration of AZA may augment
T-regulatory cell expansion, which may decrease the risk of
GVHD, as observed in mouse models.12 It will therefore be
of interest to explore whether AZA coadministration re-
duces the risk of GVHD when LEN is administered early
post-transplantation.
To obtain the MTD in such a complex patient population,
we adopted a tailored CRM design that integrates important
clinical judgements. The CRM provides greater accuracy in
its determination of the MTD compared with common rule-
based designs and both Modiﬁed Toxicity Probability In-
terval and Bayesian Optimal Interval.19,25 Implementing an
early stopping criterion that permitted clinical judgement in
this population was also of value to manage excessive DLTs
seen at the starting and lower doses in addition to having
favorable statistical properties. This is enabled via use of a
novel investigator-oriented tool, the DTP, which maps out
dose decisions in advance. This is the ﬁrst trial, to our
knowledge, that has implemented a tailored CRM coupled
with DTP, translating a complex dose-ﬁnding design to
simple decision making for trialists. Beneﬁts of using this
innovative design were seen not only at the design stage but
also during the running of the trial with the ease of visu-
alization of dose pathways simplifying the statistical black
box of complex designs. In addition, assessment of the
MTD in this high-risk patient population was accelerated by
the adoption of such a ﬂexible design, which coped ef-
fectively with the challenges of unexpected dosing error
and cohort size variation due to early patient dropout, not
necessarily requiring replacement of all patients who were
inevaluable. Because such unintended deviations could
lead to different pathways for subsequent cohorts (which
were originally planned for cohort size of three at the
model’s recommended doses), the DTP could be easily
updated (Appendix Fig A5 [online only] provides a ﬂow
diagram of a DTP and two possible updates). These have
collectively led to substantial savings in time and resources.
Such unforeseen occurrences would have been difﬁcult for
a conventional 3 + 3 design. At the point of the ﬁnal de-
termination of the MTD, 62% (13 of 21) patients had been
treated at the MTD. Implementation of the CRM allowed for
more accurate determination of the MTD while treating the
majority of patients at an optimal dose level.
T cells are a major arm of the anticancer immune response
post-allograft, yet controversy remains over their functional
state in AML.26,27 In a smaller cohort, T-cell exhaustion in
patients with AML may predict relapse post–allo-SCT.28
Correspondingly, we have shown that the T cells in pa-
tients post-transplantation have an exhaustion phenotype
manifested by increased PD1 and LAG3 expression, in
combination with reduced interferon-g, tumor necrosis
factor–a, IL-2, IL-5, and IL-6 secretion. We show that
combined AZA/LEN therapy does not reverse the T-cell
phenotype, and T-cell status does not correlate with re-
sponse to these agents post-allograft. The ﬁndings extend
our previous results that AML creates an immunosup-
pressive microenvironment to T cells.29 Alternative ap-
proaches to reverse T-cell exhaustion could be an adjunct
to enhance post-transplantation immune surveillance for
patients with AML.
Our data establish a potentially important role for an LEN/
AZA combination as salvage therapy in patients with re-
lapsed AML post-allograft and support a randomized
comparison of this novel regimen with intensive chemo-
therapy in this area of major unmet need. Alternatively,
combined LEN/AZA therapy could be administered either
as maintenance therapy15 or, because of the requirement
for at least three cycles of therapy to maximize response,
pre-emptively in patients with evidence of measurable
residual disease.
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Cohort 1 - Dose 0: 75mg/m2 Azacitidine + 5mg Lenalidomide; 0/3 DLT
Cohort 2 - Dose 1: 75mg/m2 Azacitidine + 10mg Lenalidomide; 0/3 DLT
Cohort 3 - Dose 2: 75mg/m2 Azacitidine + 15mg Lenalidomide; 0/2 DLT,
75mg/m2 Azacitidine + 25mg Lenalidomide: 0/1 DLT *
Cohort 4 - Dose 3: 75mg/m2 Azacitidine + 25mg Lenalidomide; 0/2 DLT
Cohort 5 - Dose 3: 75mg/m2 Azacitidine + 25mg Lenalidomide; 1
(Fatigue + Rash) / 3 DLT
Cohort 6 - Dose 3: 75mg/m2 Azacitidine + 25mg Lenalidomide; 1
(Deranged LFTs) / 3 DLT
Cohort 7 - Dose 3: 75mg/m2 Azacitidine + 25mg Lenalidomide; 0/4 DLT
FIG A1. Continual reassessment model dose-toxicity curves. This
ﬁgure shows how the estimates of the probabilities of dose-limiting
toxicities (DLTs) at each dose evolve from the initial guesses of DLT
(prior curve) to the ﬁnal cohort 7. The dose-toxicity curves initially
dropped from cohorts 1 to 4 (because no DLT was observed at all
tested doses) and only increased when DLTs were observed for
cohorts 5 and 6 at 25 mg lenalidomide. (*) One patient was in-
correctly treated with dose level 3 in cycle 1.
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FIG A2. Trial Steering Committee (TSC) dose decisions by cohort. MTD, maximum tolerated dose.
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FIG A3. Overall survival: responders/nonresponders. Kaplan-Meier overall survival curves for non-responders (solid
line) and responders (complete remission/complete remission with incomplete blood count recovery/partial response;
dashed line) were assessed in 15 evaluable patients who received at least three cycles of treatment. Overall survival
time was seen to be greater in those patients who responded to treatment (P = .004). Nnr, non-responders; Rspn,
responders.
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FIG A4. Expression of proinﬂammatory
cytokines in healthy donors and patients
with acute myeloid leukemia (AML). Re-
lease of proinﬂammatory cytokines IL-2,
IL-5, and IL-6 were reduced in the patients
with AML compared with healthy donors.
(A) Concentrations of IL-2 and Il-9 in the
supernatants of stimulated peripheral
blood mononuclear cells (PBMCs) from all
patients. (B) Concentrations of T helper 2
cells (Th2) cytokines in the supernatants
of stimulated PBMCs from all patients. (C)
Concentrations of Th17 cytokines in the
supernatants of stimulated PBMCs from
all patients.
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FIG A5. Dose transition pathways (DTP) ﬂow diagrams. Flow diagrams presenting the different pathways for dose (d) recommendations on the
basis of the possible patient outcome permutations within the trial for future cohorts (C). (A) DTP for C3 to C5 on the basis of no observed DLTs for
C1 and C2: (zero of three at dose 0 and zero of three at dose 1). The recommended dose for C3 is dose 2. The DTP for subsequent cohorts only
apply if the cohort size is three at the recommended dose. (B, C) Two scenarios where this is not the case. (B) Scenario in which C3 consist of two
patients who received dose level 2 and one patient received dose level 3, with no dose-limiting toxicities (DLTs) experienced. (C) Scenario in which
C3 consist of two patients who received dose level 2 and one patient received dose level 3, with no DLT at dose level 2 but a DLT experienced by the
patient who received dose level 3.
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